First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective study aims to evaluate the real-world effectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Moliner, MD, Núria Zellweger, MSc, Sabine Schmid, MD, Martina Bertschinger, MD, Christine Waibel, MD, Ferdinando Cerciello, MD, PhD, Patrizia Froesch, MD, Michael Mark, MD, Adrienne Bettini, MD, Pirmin Häuptle, MD, Veronika Blum, MD, Lisa Holer, MSc, Stefanie Hayoz, PhD, Martin Früh, MD, Samreen Ahmed, FRCP, MD, MBBS, MSc, Shradha Bhagani, MD, Nicola Steele, MD, Hannah-Leigh Gray, BSc, Stephen D. Robinson, MD, Michael Davidson, MD (Res), Samantha Cox, MD, MSc, MBBCh, Taha Khalid, MD, Tom R. Geldart, MD, Luke Nolan, FRCS, PhD, Deborah C. Scott, MBChB (MRCP), Lindsay Hennah, MD, Tom Newsom-Davis, MD, PhD, Emma Rathbone, MD, PhD, Catherine Handforth, MD, Arshi Denton, MD, Shairoz Merchant, PhD, Fiona Blackhall, MD, PhD, Laetitia A. Mauti, MD, Raffaele Califano, MD, Sacha I. Rothschild, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JTO Clinical and Research Reports
Subjects:
SCLC
Real-world data
Immunotherapy
Special populations
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001140
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items